Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: Allan Harris who wrote (246)	7/13/2004 5:02:27 PM
From: tuck	Respond to of 510

They haven't been too forthcoming, as the whole proteomic diagnostics market is fuzzy right now (AFFX and Roche are facing similar issues with their gene chip based tests). Early results by various teams have had reproducibility issues. I think everyone that is actually ready to commercialize is talking to the FDA about trials or the need for them. A sense of the situation can be gleaned here: myhealthsense.com Perhaps we will hear more at Chips to Hits, in Boston this September. Ciphergen is presenting about OvaSure, the name of their test. If by closing competition, Piper is talking about these folks mentioned in the article, well, where have they been? Most of them have been around and known to us for years; it's not gotten much different, there's no clear leader in the clinical diagnostics race yet. In chips . . . Unclear to me if SomaLogic and Zyomyx are selling many chips. They're private. I haven't come across publications utilizing their stuff, and I HAVE looked. Ciphergen, by contrast, can boast several hundred, a number of which I have posted here. If trials are required, they should go pretty quickly, IMO. Ironing out regulatory issues with the FDA will take longer. Cheers, Tuck